Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6681)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO STRATEGIC COOPERATION AGREEMENT TO EXPAND INTO THE MALAYSIA MARKET AND DEEPEN INTERNATIONAL POSITIONING

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司(the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purposes of keeping the investors informed of the latest update on the business developments of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the Company has entered into a strategic cooperation agreement (the "**Agreement**") with DODR Technology Ltd. (絲路之舟科技有限公司) ("**DODR**"), pursuant to which both parties thereto will carry out in-depth strategic cooperation in fields such as the localization, market promotion and scientific research transformation of cognitive impairment digital therapeutics products in Malaysia and the Southeast Asia region as their joint efforts to promote the development of the digital health industry.

BACKGROUND AND CONTENT OF COOPERATION

As one of the important economies in Southeast Asia, Malaysia is facing the challenges of a rapidly aging population and rising demand for mental health. According to data from the Department of Statistics Malaysia, the population aged 60 and above in the country reached 3.8 million in 2023. At the same time, mental health issues among adolescents have also become increasingly prominent. Although the Malaysian government has promoted several mental health policies, diagnostic and treatment resources remain scarce, with the ratio of psychological counselors being only 1:52,000, which is far below the international standard of 1:500, creating a significant market gap.

As a pioneer in China's cognitive impairment digital therapeutics market, the Company's core product, the "Brain Function Information Management Platform Software System", is the first cognitive impairment digital therapeutics product in China to receive regulatory approval and has been included in the provincial medical insurance reimbursement lists of 30 provinces across China.

The parent company of DODR, China Silk Road Group Co., Ltd. (中國絲路集團有限公司) ("**Silk Road Group**"), is a comprehensive multinational group practicing the "Belt and Road" initiative, adhering to the concept of "extensive consultation, joint contribution and shared benefits", and driving industrial integration through digital technology. Silk Road Group has pioneered technical foundations such as Digital Trade Infrastructure (DTI) and constructed a business matrix covering "Digital Silk Road" and "Health Silk Road". It has assisted over a hundred enterprises in achieving breakthroughs in overseas revenue, with its digital trade platform achieving an annual transaction volume of over RMB20 billion and its digital logistics platform accumulating shipments of over 170 million pieces. In the field of healthcare, Silk Road Group relies on its self-developed digital medical platform D-Health to promote cross-border synergy of medical resources exceeding RMB5 billion, and has long carried out international medical assistance and public welfare projects, possessing profound capabilities in cross-border resource integration and localization. It possesses deep government public resources, medical industry channel networks, and project operation experience in Malaysia and various Southeast Asian countries, with strong capabilities in local policy interpretation, resource matching, and project implementation.

Pursuant to the Agreement, the cooperation between the parties thereto mainly includes the following:

(I) Construction of specialized laboratory: DODR will assist the Company in establishing a "Cognitive Impairment Digital Therapeutics Specialized Laboratory" in Malaysia, coordinating matters such as local approvals, site planning, and equipment importation; the Company will provide technical solutions and scientific research support, and lead the research, development, and operation.

(II) Application for national innovation pilot Proof of Concept projects: DODR will take the lead in liaising with relevant Malaysian authorities to assist the Company in applying for national innovation pilot Proof of Concept projects; both parties will jointly promote the application and implementation.

(III) Implementation of clinical trials in hospitals: DODR will screen and connect with target hospitals to promote the signing of clinical trial cooperation agreements; the Company will be responsible for product localization and adaptation, medical staff training, and data collection.

(IV) Market expansion synergy in Malaysia: both parties thereto will integrate resources such as products, channels, and brands to jointly carry out market promotion and commercialization.

(V) Cooperation in Southeast Asia market expansion: based on the cooperation in Malaysia, the cooperation will gradually expand to other Southeast Asian countries such as Indonesia, Thailand, and Vietnam.

The Agreement is a framework agreement entered into by both parties in relation to collaborations in the Malaysia and Southeast Asia markets, and the specific execution details thereof will be subject to further operational terms to be agreed upon by both parties.

REASONS FOR AND BENEFITS OF THE COOPERATION

The Board believes that this cooperation will present long-term development opportunities to the Company, thereby creating sustainable value for the shareholders, specifically:

(I) deepening international positioning and expanding overseas markets: the Company has successively commenced business promotion and operations in Hong Kong, Macau and Singapore, accumulating experience in overseas markets. This cooperation with DODR marks the official entry of the Company into the Malaysia market and further expands its business network in Southeast Asia. This move helps to systematically export the digital therapeutics experience and technical system verified by the Company in the China market to other regions that demonstrate growth potential and policy support, further expanding the Company's international brand influence and business coverage, and enhancing its global presence;

(II) leveraging local resources to accelerate market implementation: DODR possesses extensive government and medical resource networks in Malaysia, which can assist the Company in efficiently completing product access, channel connection, and pilot implementation, thereby shortening the market introduction cycle and improving commercial conversion efficiency; and

(III) enhancing brand influence and regional synergy: this cooperation further strengthens the Company's brand authority and professional image in the digital healthcare sector. Leveraging DODR's medical industry channel networks in Malaysia and various Southeast Asian countries, the Company can accelerate the implementation of products in local medical institutions, shorten the market introduction cycle, and expand into diversified markets such as digital health management.

IMPLICATIONS UNDER THE LISTING RULES

To the best of the knowledge and belief of the Company, DODR and its ultimate beneficial owners are independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). The transactions contemplated under this cooperation do not constitute any connected transaction of the Company under Chapter 14A of the Listing Rules, nor does it constitute any notifiable transaction of the Company under Chapter 14 of the Listing Rules.

The Cooperation is in the initial execution stage. Actual progress and outcomes may be influenced by various factors including the implementation progress, policy environment, and market acceptance. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Mr. Tan Zheng
Chairman and Executive Director

Hong Kong, February 5, 2026

As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.